+1 617 937 2316 mrecht@cooley.com
For over 20 years, Marc Recht has represented life sciences and other healthcare companies and investors in public and private transactions, including securities offerings, joint ventures and M&A matters. He also has extensive experience advising public companies boards of directors and management teams regarding Securities and Exchange Commission periodic disclosure, Sarbanes-Oxley compliance, corporate governance and Nasdaq and New York Stock Exchange rules.
Download full bio
Celularity to Go Public Through SPAC Merger
Oncorus – $98 Million IPO
RenalytixAI – $85 Million IPO
Repare Therapeutics - $253 Million IPO
Calliditas Therapeutics - $90 Million IPO
View all
Public Companies
Capital Markets
Life Sciences
Mergers & Acquisitions
Emerging Companies
Medtech
Digital Health
Venture Capital
Road cycling
Skiing
Excellent in all categories. Marc Recht is 'very technically skilled in corporate matters and plays a strong quarterback role.'
Boston College Law SchoolJD, magna cum laude, 1999
Brandeis University BA, with honors, 1995
Massachusetts
Celularity to Go Public Through SPAC Merger January 13, 2021
Proteostasis Therapeutics Enters Merger Agreement With Yumanity Therapeutics August 25, 2020
Legal 500 US 2020 Highlights Cooley June 24, 2020
Chambers USA: Corporate/M&A: Capital Markets - Massachusetts (2014-2020)
The Legal 500 US: Healthcare: Life Sciences (2013, 2016, 2020)
Who's Who Legal: Life Sciences (2017, 2018)
Super Lawyers: Rising Star (2007, 2010-2013)
Boston Business Journal: Biotech IPO (2015)
+1 617 937 2316 office +1 617 937 2400 fax mrecht@cooley.com
500 Boylston Street14th FloorBoston, MA 02116-3736